ARVINAS INC (ARVN) Stock Price, Quote, News and Overview
NASDAQ:ARVN - Nasdaq - US04335A1051 - Common Stock - Currency: USD
ARVN Quote, Performance and Key Statistics
7.23
-2.39 (-24.84%)
The current stock price of ARVN is 7.23 USD. In the past month the price increased by 0.7%. In the past year, price decreased by -77.97%.
ARVN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 61.08 | 752.80B | ||
| JNJ | JOHNSON & JOHNSON | 15.37 | 372.23B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.96 | 291.20B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.21 | 219.89B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.95 | 218.61B | ||
| MRK | MERCK & CO. INC. | 10.69 | 209.51B | ||
| PFE | PFIZER INC | 7.45 | 135.72B | ||
| SNY | SANOFI-ADR | 14.02 | 132.44B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.76 | 100.96B | ||
| GSK | GSK PLC-SPON ADR | 7.05 | 78.52B | ||
| ZTS | ZOETIS INC | 26.29 | 69.43B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.67 | 47.30B |
Related stock screener links
About ARVN
Company Profile
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 430 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Company Info
ARVINAS INC
5 Science Park
New Haven CONNECTICUT 06511 US
CEO: John Houston
Employees: 445
Company Website: https://www.arvinas.com/
Investor Relations: https://ir.arvinas.com/
Phone: 12035351456
ARVINAS INC / ARVN FAQ
What is the stock price of ARVINAS INC today?
The current stock price of ARVN is 7.23 USD. The price decreased by -24.84% in the last trading session.
What is the ticker symbol for ARVINAS INC stock?
The exchange symbol of ARVINAS INC is ARVN and it is listed on the Nasdaq exchange.
On which exchange is ARVN stock listed?
ARVN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARVINAS INC stock?
28 analysts have analysed ARVN and the average price target is 32.52 USD. This implies a price increase of 349.79% is expected in the next year compared to the current price of 7.23. Check the ARVINAS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARVINAS INC worth?
ARVINAS INC (ARVN) has a market capitalization of 497.21M USD. This makes ARVN a Small Cap stock.
How many employees does ARVINAS INC have?
ARVINAS INC (ARVN) currently has 445 employees.
What are the support and resistance levels for ARVINAS INC (ARVN) stock?
ARVINAS INC (ARVN) has a resistance level at 13.35. Check the full technical report for a detailed analysis of ARVN support and resistance levels.
Is ARVINAS INC (ARVN) expected to grow?
The Revenue of ARVINAS INC (ARVN) is expected to decline by -28.23% in the next year. Check the estimates tab for more information on the ARVN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARVINAS INC (ARVN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARVN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARVN, evaluating the profitability, health, valuation and growth aspects
- ARVINAS INC (ARVN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARVINAS INC (ARVN) Sales and EPS estimates to see what analysts future expectations are.
- ARVINAS INC (ARVN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARVINAS INC (ARVN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARVINAS INC (ARVN) Stock Chart to make your own analysis
- ARVINAS INC (ARVN) Latest news and press-releases to stay up to date.
Does ARVINAS INC (ARVN) stock pay dividends?
ARVN does not pay a dividend.
When does ARVINAS INC (ARVN) report earnings?
ARVINAS INC (ARVN) will report earnings on 2025-05-06, before the market open.
What is the Price/Earnings (PE) ratio of ARVINAS INC (ARVN)?
ARVINAS INC (ARVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.77).
What is the Short Interest ratio of ARVINAS INC (ARVN) stock?
The outstanding short interest for ARVINAS INC (ARVN) is 12.38% of its float. Check the ownership tab for more information on the ARVN short interest.
ARVN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ARVN. When comparing the yearly performance of all stocks, ARVN is a bad performer in the overall market: 97.83% of all stocks are doing better.
ARVN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARVN. The financial health of ARVN is average, but there are quite some concerns on its profitability.
ARVN Financial Highlights
Over the last trailing twelve months ARVN reported a non-GAAP Earnings per Share(EPS) of -2.77. The EPS increased by 57.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.22% | ||
| ROE | -35.41% | ||
| Debt/Equity | 0 |
ARVN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ARVN. The Buy consensus is the average rating of analysts ratings from 28 analysts.
For the next year, analysts expect an EPS growth of -41.53% and a revenue growth -28.23% for ARVN